241 related articles for article (PubMed ID: 26052251)
1. Expression of long non-coding RNA DLX6-AS1 in lung adenocarcinoma.
Li J; Li P; Zhao W; Yang R; Chen S; Bai Y; Dun S; Chen X; Du Y; Wang Y; Zang W; Zhao G; Zhang G
Cancer Cell Int; 2015; 15():48. PubMed ID: 26052251
[TBL] [Abstract][Full Text] [Related]
2. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA DLX6-AS1 silencing inhibits malignant phenotypes of gastric cancer cells.
Fu X; Tian Y; Kuang W; Wen S; Guo W
Exp Ther Med; 2019 Jun; 17(6):4715-4722. PubMed ID: 31105791
[TBL] [Abstract][Full Text] [Related]
4. Exosomal long non-coding RNA DLX6-AS1 as a potential diagnostic biomarker for non-small cell lung cancer.
Zhang X; Guo H; Bao Y; Yu H; Xie D; Wang X
Oncol Lett; 2019 Nov; 18(5):5197-5204. PubMed ID: 31612030
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of long noncoding RNA DLX6-AS1 inhibits migration and invasion of thyroid cancer cells by upregulating UPF1.
Zhong ZB; Wu YJ; Luo JN; Hu XN; Yuan ZN; Li G; Wang YW; Yao GD; Ge XF
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10867-10873. PubMed ID: 31858555
[TBL] [Abstract][Full Text] [Related]
6. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC).
He R; Zhang FH; Shen N
Biomed Pharmacother; 2017 Nov; 95():331-338. PubMed ID: 28858731
[TBL] [Abstract][Full Text] [Related]
7. LncRNA
Sun W; Zhang L; Yan R; Yang Y; Meng X
Onco Targets Ther; 2019; 12():3945-3954. PubMed ID: 31190891
[No Abstract] [Full Text] [Related]
8. Long noncoding RNA DLX6-AS1 promotes neuroblastoma progression by regulating miR-107/BDNF pathway.
Zhang HY; Xing MQ; Guo J; Zhao JC; Chen X; Jiang Z; Zhang H; Dong Q
Cancer Cell Int; 2019; 19():313. PubMed ID: 31787850
[TBL] [Abstract][Full Text] [Related]
9. Serum Exosomal lncRNA DLX6-AS1 Is a Promising Biomarker for Prognosis Prediction of Cervical Cancer.
Ding XZ; Zhang SQ; Deng XL; Qiang JH
Technol Cancer Res Treat; 2021; 20():1533033821990060. PubMed ID: 33550924
[TBL] [Abstract][Full Text] [Related]
10. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer.
An Y; Chen XM; Yang Y; Mo F; Jiang Y; Sun DL; Cai HH
Cancer Cell Int; 2018; 18():143. PubMed ID: 30250401
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
Zhao J; Liu HR
Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
[TBL] [Abstract][Full Text] [Related]
12. LncRNA DLX6-AS1 promotes laryngeal squamous cell carcinoma growth and invasion through regulating miR-376c.
Yang Q; Sun J; Ma Y; Zhao C; Song J
Am J Transl Res; 2019; 11(11):7009-7017. PubMed ID: 31814904
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between long non-coding RNA DLX6-AS1, microRNAs and signaling pathways: A pivotal molecular mechanism in human cancers.
Alizadeh A; Jebelli A; Baradaran B; Amini M; Oroojalian F; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Gene; 2021 Feb; 769():145224. PubMed ID: 33059027
[TBL] [Abstract][Full Text] [Related]
14. Promising long noncoding RNA DLX6-AS1 in malignant tumors.
Xue C; Lv L; Jiang J; Li L
Am J Transl Res; 2020; 12(12):7682-7692. PubMed ID: 33437353
[TBL] [Abstract][Full Text] [Related]
15. DLX6-AS1: An Indispensable Cancer-related Long Non-coding RNA.
Hu C; Liu K; Wang B; Xu W; Lin Y; Yuan C
Curr Pharm Des; 2021; 27(9):1211-1218. PubMed ID: 33121401
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA DLX6-AS1 promotes breast cancer progression via miR-505-3p/RUNX2 axis.
Zhao P; Guan H; Dai Z; Ma Y; Zhao Y; Liu D
Eur J Pharmacol; 2019 Dec; 865():172778. PubMed ID: 31705901
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer.
You Q; Shi HY; Gong CF; Tian XY; Li S
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6429-6435. PubMed ID: 31378881
[TBL] [Abstract][Full Text] [Related]
18. Expression of lncRNA DLX6-AS1 in patients with hepatic carcinoma and its prognostic value.
Lin Y; Zhang B; Su L; Wei J; Chen Z; Wu M
Biotechnol Genet Eng Rev; 2023 Apr; ():1-12. PubMed ID: 37078565
[TBL] [Abstract][Full Text] [Related]
19. DLX6-AS1: A Long Non-coding RNA With Oncogenic Features.
Ghafouri-Fard S; Najafi S; Hussen BM; Ganjo AR; Taheri M; Samadian M
Front Cell Dev Biol; 2022; 10():746443. PubMed ID: 35281110
[TBL] [Abstract][Full Text] [Related]
20. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
